
Protecting Retinal Ganglion Cells
This article summarizes published findings from Catalyst for a Cure (CFC1) research scientists and subsequent discoveries by Dr. Rebecca Sappington’s lab at Vanderbilt and Wake Forest.
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
This is the place for the latest information about our work here at Glaucoma Research Foundation and for current events in the world of eye health. All breakthroughs and insights are made possible through the dedication of researchers, and through the continued financial support and active involvement of the community.
This article summarizes published findings from Catalyst for a Cure (CFC1) research scientists and subsequent discoveries by Dr. Rebecca Sappington’s lab at Vanderbilt and Wake Forest.
The groundbreaking collaborative research program will explore common characteristics of glaucoma and Alzheimer’s.
…
“Eyes On Eyecare” is dedicated to furthering research worldwide by providing clinical and career education to younger optometrists and ophthalmologists.
While it’s uncommon for people to have an allergic reaction to eye drops, it can happen. …
Since 1980, the American Academy of Ophthalmology has presented a named lecture in honor of pioneering glaucoma specialist Robert N. Shaffer, MD in conjunction with their annual meeting.
Some allergy medications include ingredients that can cause pupil dilation resulting in a condition called acute angle-closure glaucoma.
Eye pressure can vary hourly, daily, and weekly. Measuring your intraocular pressure (IOP) during eye exams provides an important indication of your eye health.
Exercise for glaucoma patients can be beneficial. Research has shown that regular exercise lowers intraocular pressure (IOP) in glaucoma patients.
A number of medications are currently in use to treat glaucoma. …
When Glaucoma Research Foundation first launched Catalyst for a Cure in 2002, our bold idea was to recruit the most promising young researchers from different fields to work collaboratively.
Pilot project grants support new and promising ideas in the field of glaucoma research.
Some people may have early warning signs, but most patients will not notice any vision loss until the disease is at a late stage. …
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
The Gleams Newsletter includes interviews, personal stories, and current information about glaucoma, new treatments, updates on research findings, and more. You can subscribe to the printed version of Gleams or the electronic version — both are free.
FOR EYECARE PROFESSIONALS
FOR EYECARE PROFESSIONALS
Glaucoma Research Foundation • 251 Post Street, Suite 600 • San Francisco, CA 94108 • 415-986-3162
Send us an email
We are a 501c3 tax-exempt national nonprofit. Our tax ID number is 94-2495035. Our EIN number is 94-2495035.
Copyright 2023 all rights reserved.